A Randomized Trial of AM0010 in Combination with Nivolumab vs Nivolumab Alone as Second Line Therapy in Subjects with Stage IV Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (17201)

A Randomized Trial of AM0010 in Combination with Nivolumab vs Nivolumab Alone as Second Line Therapy in Subjects with Stage IV Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (17201)

Trial Category:
Lung
Phase
II
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Nebraska Cancer Specialists, Omaha, NE
Nebraska Hematology Oncology, Lincoln, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members